Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis. 1998

M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
Department of Molecular Immunology, Institute of Development, Aging and Cancer, School of Medicine, Tohoku University, Sendai, Japan.

The AML1 gene, which encodes the DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF, is involved in several types of chromosomal translocations associated with human acute myeloid leukemia, and has been shown by gene targeting to be essential for the development of definitive hematopoiesis in the murine fetal liver. In addition, the gene is expressed abundantly in T lymphocytes and has been implicated in T cell specific gene expression. In the present study we examined the function of AML1 in T cell receptor (TCR)-mediated, Fas/Fas-ligand dependent apoptosis of a T hybridoma line, DO11.10. Several independent cell clones overexpressing the AML1 protein were isolated by transfecting AML1 cDNA into these cells. These clones possessed an increased level of PEBP2/CBF DNA binding activity and were found to be resistant to apoptosis induced by anti-CD3 antibody treatment. Northern blot analysis revealed that induction of the Fas-ligand transcript was markedly suppressed in the anti-CD3 treated clones. Instead, expression of IL-2 receptor alpha subunit (IL-2R alpha), which is a manifestation of proliferative TCR signaling, was induced. This was in contrast to the parental, anti-CD3 treated DO11.10 cells where induction of Fas-ligand but not of IL-2R alpha was observed. Resistance of the AML1 overexpressing cell clones to TCR-mediated apoptosis is most likely attributable to the lack of Fas-ligand induction, since simultaneous treatment with anti-CD3 and anti-Fas antibodies caused apoptosis of the clones. The overall results suggest that the AML1 protein may play a pivotal role in switching TCR signaling between apoptosis and cell proliferation in T lymphocytes.

UI MeSH Term Description Entries
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription

Related Publications

M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
April 2004, Free radical biology & medicine,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
October 2002, International journal of hematology,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
February 2024, Nature communications,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
June 2008, Oncogene,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
January 2013, The Journal of experimental medicine,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
February 1992, Cancer research,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
January 2015, Cellular immunology,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
February 2015, Circulation,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
December 1997, The Journal of experimental medicine,
M Fujii, and K Hayashi, and M Niki, and N Chiba, and K Meguro, and K Endo, and J Kameoka, and S Ito, and K Abe, and T Watanabe, and M Satake
March 1997, Immunology,
Copied contents to your clipboard!